Physician profile

Daniel A Tramuta

Cardiovascular Disease · Cincinnati, OH

NPI 1902803612

$11,024.66

in general payments reported to CMS, 2019-2025

42 companies · $166 in 2025

The $166 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,436.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,331.30 2019-2024 Wolverine Coronary Cutting Balloon, Avvigo Guidance System, Watchman Access System
Medtronic Vascular, INC. $1,021.39 2019-2020
Novartis Pharmaceuticals Corporation $1,017.85 2019-2023
Janssen Pharmaceuticals, INC $983.72 2019-2023 Xarelto
Amgen INC. $972.79 2019-2025 Repatha, Repatha
Abbott Laboratories $798.02 2019-2022
Abiomed $761.07 2019-2024 Impella
Medtronic, INC. $540.96 2021-2024 Onyx Frontier, Ffrangio
E.R. Squibb & Sons, L.L.C. $435.32 2019-2024 Camzyos
Bardy Diagnostics, INC. $261.97 2019-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $258.79 2019-2023 Lifevest
Edwards Lifesciences Corporation $254.43 2019-2023 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Sanofi-Aventis U.S. LLC $245.44 2019
Boehringer Ingelheim Pharmaceuticals, INC. $220.94 2020-2024 Jardiance
Irhythm Technologies, INC. $195.88 2019-2022
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Terumo Medical Corporation $176.09 2019-2024
Amarin Pharma, INC. $152.19 2019-2022
Astrazeneca Pharmaceuticals LP $145.47 2019-2022
Merck Sharp & Dohme LLC $141.61 2021-2022
Lantheus Medical Imaging, INC. $136.35 2019-2020
Penumbra, INC. $132.64 2023 Indigo System
Inari Medical, INC. $118.92 2023 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Regeneron Healthcare Solutions, INC. $84.63 2019
Pfizer INC. $80.05 2019-2023
Cardiovascular Systems INC. $63.57 2019-2021
Reflow Medical INC $63.45 2024
Bayer Healthcare Pharmaceuticals INC. $53.16 2021-2022
Baxter Healthcare $49.30 2025 Hillrom - Cardiac Ambulatory Monitor
Chiesi USA, INC. $44.13 2019-2020
Ekos Corporation $36.57 2019
Livanova USA, INC. $34.52 2020
Astellas Pharma US INC $31.80 2019-2020
Cook Medical LLC $27.03 2019
Medtronic USA, INC. $25.40 2019
Vital Connect, INC $18.79 2024 Vitalpatch Rtm
Atricure, INC. $18.33 2023
Lundbeck LLC $17.80 2019
Actelion Pharmaceuticals US, INC. $16.83 2020
Philips North America LLC $16.74 2024 (Ck7) Extended Holter
Daiichi Sankyo INC. $15.56 2019
Gilead Sciences, INC. $12.65 2019
Esperion Therapeutics, INC. $11.21 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel A Tramuta

$11,024.66

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $166 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/85817/daniel-a-tramuta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.